NHS Blood and Transplant

Board Meeting in Public
Tuesday, 21 July 2026

Title of Paper	Board Level Policy 8 – Business Continuity	**Agenda No.**	4.2
Nature of Paper	☒ Official	☐ Official Sensitive	
Author(s)	Richard Rackham, AD Governance and Resilience Tom Cowdrey, Head of Business Continuity		
Lead Executive	Helen Gillan, Director of Quality and Governance		
Non-Executive Director Sponsor	N/A		
Presenter(s) at Meeting	Helen Gillan, Director of Quality and Governance		
Presented for	☒ Approval ☐ Assurance	☐ Information ☐ Update	
Is there a plan to communicate this to the organisation?	☒ Yes	☐ No	☐ Yet to be determined

Executive Summary

The Business Continuity Policy is submitted for approval on an annual basis. The Policy sets out:

- responsibilities to the commissioning of the Business Continuity and Emergency Planning Programmes
- Business Continuity Training
- Oversight of these programmes

The Board is asked for its approval and that there is no requirement change.

Previously Considered by

This Policy was signed off by the Board in 2025-26. The policy was considered by the Audit, Risk and Governance Committee on 24 June 2026.

Recommendation

The Board is asked to approve the Policy

Risk(s) identified (Link to Board Assurance Framework Risks)

The risks most closely linked with this policy are P-02 Service Disruption and P-03 Loss of Critical ICT. The policy is the basis of the Business Continuity Management System which is a major control for both of these risks

Strategic Objective(s) this paper relates to:

☐ Collaborate with partners	☐ Invest in people and culture	☒ Drive innovation
☒ Modernise our operations	☐ Grow and diversify our donor base	

Appendices:	BLP 8